Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
ATAI Stock Chart & Stats
$3.40
-$0.11(-6.29%)
At close: 4:00 PM EST
$3.40
-$0.11(-6.29%)
Day’s Range― - ―
52-Week Range$1.15 - $6.75
Previous CloseN/A
Volume1.44M
Average Volume (3M)5.30M
Market Cap
$1.24B
Enterprise Value$584.50M
Total Cash (Recent Filing)$256.04M
Total Debt (Recent Filing)$2.07M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding364,745,970
10 Day Avg. Volume5,439,805
30 Day Avg. Volume5,298,268
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue142.95
Enterprise Value/Gross Profit189.96
Enterprise Value/Ebitda-5.17
Forecast
1Y Price Target
$14.10Price Target Upside314.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$466.67K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyTwo-dose induction data showed larger and sustained reductions in depressive symptoms versus a single-dose approach, indicating the regimen could provide meaningful and durable benefit for patients.
Regulatory ProgressCompletion of an End-of-Phase two meeting with the FDA and receipt of Breakthrough Therapy designation support a clear path to a pivotal program and lessen late-stage regulatory risk.
Scientific Validation And Partnership InterestPublication of mid-stage data in a peer-reviewed journal combined with adviser-led efforts to seek partnerships signals external scientific credibility and potential commercial interest in the asset.
Bears Say
Clinical Safety ConcernsSeveral patient discontinuations, including transient blood pressure increases and one case of suicidal ideation in a patient with prior risk, underscore safety monitoring needs that could complicate future studies.
Financial Strain From Merger-related AccountingA large one-time accounting charge tied to the merger materially increased reported losses while elevated general and administrative costs reduce near-term financial flexibility.
Market Concentration And Execution RisksA highly concentrated target market, together with risks of clinical failure, competitor activity, and the need to raise additional capital, creates commercialization and dilution challenges for the program.
Atai Beckley N.V. News
ATAI FAQ
What was Atai Beckley N.V.’s price range in the past 12 months?
Atai Beckley N.V. lowest stock price was $1.15 and its highest was $6.75 in the past 12 months.
What is Atai Beckley N.V.’s market cap?
Atai Beckley N.V.’s market cap is $1.24B.
When is Atai Beckley N.V.’s upcoming earnings report date?
Atai Beckley N.V.’s upcoming earnings report date is May 20, 2026 which is in 49 days.
How were Atai Beckley N.V.’s earnings last quarter?
Currently, no data Available
Is Atai Beckley N.V. overvalued?
According to Wall Street analysts Atai Beckley N.V.’s price is currently Undervalued.
Does Atai Beckley N.V. pay dividends?
Atai Beckley N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Beckley N.V. dividends here
What is Atai Beckley N.V.’s EPS estimate?
Atai Beckley N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Atai Beckley N.V. have?
Atai Beckley N.V. has 364,745,970 shares outstanding.
What happened to Atai Beckley N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Atai Beckley N.V.?
Currently, no hedge funds are holding shares in ATAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Atai Beckley N.V. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.10 (314.71% Upside)
$14.10 (314.71% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 941.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $154.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Atai Beckley N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
ATAI Stock 12 Month Forecast
Average Price Target
$14.10
▲(314.71% Upside)
Technical Analysis
Nektar Therapeutics
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
―
Praxis Precision Medicines
―
Ownership Overview
23.34% Insiders
<0.01% Mutual Funds
1.10% Other Institutional Investors
73.18% Public Companies and Individual Investors